Company newsCompany release
Johnson & Johnson presents early Phase 1 data on prostate cancer combination
No Grade 3 or higher treatment-related adverse events were reported at the recommended regimen in the Phase 1 study of pasritamig and JNJ-9401, now in Phase 3 development.
GetSignal
Johnson & Johnson said on November 8, 2026, that early Phase 1 results for its investigational combination of pasritamig and JNJ-9401 showed prostate-specific antigen (PSA) reductions in advanced prostate cancer.
At the recommended regimen, 11 of 15 patients had PSA reductions of at least 50%, and 7 of 15 had reductions of at least 90%. The company said the findings are preliminary and based on a small number of patients.
Key facts
- Recommended regimen
- JNJ-9401 200 mg subcutaneously plus pasritamig 300 mg intravenously, every six weeks
- Patients with PSA reductions of at least 50%
- 11 of 15
- Presentation
- Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, late-breaking oral session
Source: The company's release on PR Newswire, November 8, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Johnson & Johnson first, then the newest- Johnson & Johnson agrees to acquire Ollin Biosciences
JNJ · Johnson & Johnson · Company release · Nov 16, 2026
- Johnson & Johnson says CAPLYTA improved manic symptoms in second Phase 3 study
JNJ · Johnson & Johnson · Company release · Nov 10, 2026
- Johnson & Johnson presents new patient experience data on nipocalimab in Sjögren's disease
JNJ · Johnson & Johnson · Company release · Nov 7, 2026
